1.31

1.55% 0.02

After Hours: 1.27 -0.04 -3.05%

Ocuphire Pharma Inc (OCUP)

Overview News Price History Option Chain Financials Discussions Forecast

Ocuphire Pharma Inc stock is traded at $1.31, with a volume of 81,197. It is up +1.55% in the last 24 hours and up +5.65% over the past month. Ocuphire Pharma Inc is a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of refractive and retinal eye disorders. Ocuphire's pipeline includes two small molecular product candidates targeting the front and back of the eye indications. The Nyxol candidate is being developed for dim light or night vision disturbances, reversal of pharmacologically induced mydriasis, and presbyopia. The second product candidate, APX3330, is being developed for diabetic retinopathy and diabetic macular edema.

Previous Close:

$1.29

Open:

$1.32

24h Volume:

81,197

Relative Volume:

0.56

Market Cap:

$34.06M

Revenue:

$19.05M

Net Income/Loss:

$-9.99M

P/E Ratio:

1.5595

EPS:

0.84

Net Cash Flow:

$-1.11M

1W Performance:

-3.68%

1M Performance:

+5.65%

6M Performance:

-34.83%

1Y Performance:

-60.90%

1-Day Range:

$1.28

$1.33

1-Week Range:

$1.2502

$1.4163

52-Week Range:

$1.15

$3.76

Ocuphire Pharma Inc Stock (OCUP) Company Profile

Name

Ocuphire Pharma Inc

Sector

Healthcare (1190)

Industry

Biotechnology (681)

Phone

248-681-9815

Address

37000 GRAND RIVER AVE., FARMINGTON HILLS

Employee

Twitter

Next Earnings Date

2024-08-19

Latest SEC Filings

OCUP's Discussions on Twitter

Ocuphire Pharma Inc Stock (OCUP) Latest News

10:03 AM

Ocuphire Pharma releases results from MIRA-2 and MIRA-3 clinical trials for phentolamine ophthalmic solution 0.75% for pharmacologically-induced mydriasis - Ophthalmology Times

10:03 AM

08:06 AM

Ocuphire reports positive phase 3 results for eye treatment RYZUMVI By Investing.com - Investing.com UK

08:06 AM

08:00 AM

Ocuphire Pharma Announces Publication of Full Phase 3 - GlobeNewswire

08:00 AM

Ocuphire Pharma Announces Publication of Full Phase 3 Results of Phentolamine Ophthalmic Solution 0.75% for Pharmacologically-Induced Mydriasis in Ophthalmology - StockTitan

08:00 AM

Sep 24, 2024

Ratio Review: Analyzing Ocugen Inc (OCGN)’s Price-to-Cash and Price-to-Free Cash Flow - The Dwinnex

Sep 24, 2024

Analyzing SOPHiA GENETICS (NASDAQ:SOPH) & Cyclo Therapeutics (NASDAQ:CYTH) - Defense World

Sep 24, 2024

Sep 23, 2024

Oaktree Specialty Lending director buys shares worth over $16,000 By Investing.com - Investing.com Canada

Sep 23, 2024

Is OCGN’s price to cash per share ratio a concern for investors? - US Post News

Sep 23, 2024

Sep 21, 2024

Option Care Health, Inc. (NASDAQ:OPCH) Position Increased by First Eagle Investment Management LLC - Defense World

Sep 21, 2024

Option Care Health, Inc. (NASDAQ:OPCH) Shares Sold by DekaBank Deutsche Girozentrale - Defense World

Sep 21, 2024

Sep 20, 2024

Halozyme's ENHANZE® (HALO) Technology Empowers OCREVUS ZUNOVO™: A New Era in MS Treatment - BP Journal

Sep 20, 2024

Opaleye Management Inc. Increases Stake in Codexis Inc. - Yahoo Finance

Sep 20, 2024

Sep 19, 2024

All the Doctor Odyssey guest stars we know so far - Hidden Remote

Sep 19, 2024

Sep 18, 2024

Mydriasis Treatment Market Booming Worldwide With Leading Key - openPR

Sep 18, 2024

Full approval of PBC therapy Ocaliva rejected by FDA committee in 10-1 vote - Liver Disease News

Sep 18, 2024

American Century Companies Inc. Raises Position in Option Care Health, Inc. (NASDAQ:OPCH) - Defense World

Sep 18, 2024

Sep 17, 2024

Roche’s injectable Ocrevus Zunovo granted FDA approval to treat relapsing and primary MS - PMLiVE

Sep 17, 2024

Sep 07, 2024